Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

1.

Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.

Murrough JW, Soleimani L, DeWilde KE, Collins KA, Lapidus KA, Iacoviello BM, Lener M, Kautz M, Kim J, Stern JB, Price RB, Perez AM, Brallier JW, Rodriguez GJ, Goodman WK, Iosifescu DV, Charney DS.

Psychol Med. 2015 Aug 12:1-10. [Epub ahead of print]

PMID:
26266877
2.

Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression.

Leuchter AF, Cook IA, Feifel D, Goethe JW, Husain M, Carpenter LL, Thase ME, Krystal AD, Philip NS, Bhati MT, Burke WJ, Howland RH, Sheline YI, Aaronson ST, Iosifescu DV, O'Reardon JP, Gilmer WS, Jain R, Burgoyne KS, Phillips B, Manberg PJ, Massaro J, Hunter AM, Lisanby SH, George MS.

Brain Stimul. 2015 Jul-Aug;8(4):787-94. doi: 10.1016/j.brs.2015.05.005. Epub 2015 May 22.

PMID:
26143022
3.
4.

Genetic Differences in the Immediate Transcriptome Response to Stress Predict Risk-Related Brain Function and Psychiatric Disorders.

Arloth J, Bogdan R, Weber P, Frishman G, Menke A, Wagner KV, Balsevich G, Schmidt MV, Karbalai N, Czamara D, Altmann A, Trümbach D, Wurst W, Mehta D, Uhr M, Klengel T, Erhardt A, Carey CE, Conley ED; Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium (PGC), Ruepp A, Müller-Myhsok B, Hariri AR, Binder EB; Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium PGC.

Neuron. 2015 Jun 3;86(5):1189-202. doi: 10.1016/j.neuron.2015.05.034.

5.

The association between lower educational attainment and depression owing to shared genetic effects? Results in ~25,000 subjects.

Peyrot WJ, Lee SH, Milaneschi Y, Abdellaoui A, Byrne EM, Esko T, de Geus EJ, Hemani G, Hottenga JJ, Kloiber S, Levinson DF, Lucae S; Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium (Corporate Collaborator), Martin NG, Medland SE, Metspalu A, Milani L, Noethen MM, Potash JB, Rietschel M, Rietveld CA, Ripke S, Shi J; Social Science Genetic Association Consortium Corporate Collaborator, Willemsen G, Zhu Z, Boomsma DI, Wray NR, Penninx BW; Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium Corporate Collaborator; Social Science Genetic Association Consortium Corporate Collaborator.

Mol Psychiatry. 2015 Jun;20(6):735-43. doi: 10.1038/mp.2015.50. Epub 2015 Apr 28.

PMID:
25917368
6.

In pursuit of neuroimaging biomarkers to guide treatment selection in major depressive disorder: a review of the literature.

Lener MS, Iosifescu DV.

Ann N Y Acad Sci. 2015 May;1344:50-65. doi: 10.1111/nyas.12759. Epub 2015 Apr 8. Review.

PMID:
25854817
7.

Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder.

Murrough JW, Collins KA, Fields J, DeWilde KE, Phillips ML, Mathew SJ, Wong E, Tang CY, Charney DS, Iosifescu DV.

Transl Psychiatry. 2015 Feb 17;5:e509. doi: 10.1038/tp.2015.10.

8.

The association of post-stroke anhedonia with salivary cortisol levels and stroke lesion in hippocampal/parahippocampal region.

Terroni L, Amaro E Jr, Iosifescu DV, Mattos P, Yamamoto FI, Tinone G, Conforto AB, Sobreiro MF, Guajardo VD, De Lucia MC, Moreira AC, Scaff M, Leite CC, Fraguas R.

Neuropsychiatr Dis Treat. 2015 Feb 3;11:233-42. doi: 10.2147/NDT.S73722. eCollection 2015.

9.

The promise of ketamine for treatment-resistant depression: current evidence and future directions.

DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Iosifescu DV.

Ann N Y Acad Sci. 2015 May;1345:47-58. doi: 10.1111/nyas.12646. Epub 2015 Feb 3.

PMID:
25649308
10.

Seasonality shows evidence for polygenic architecture and genetic correlation with schizophrenia and bipolar disorder.

Byrne EM; Psychiatric Genetics Consortium Major Depressive Disorder Working Group, Raheja UK, Stephens SH, Heath AC, Madden PA, Vaswani D, Nijjar GV, Ryan KA, Youssufi H, Gehrman PR, Shuldiner AR, Martin NG, Montgomery GW, Wray NR, Nelson EC, Mitchell BD, Postolache TT.

J Clin Psychiatry. 2015 Feb;76(2):128-34. doi: 10.4088/JCP.14m08981.

PMID:
25562672
11.

The influence of depressive symptoms on quality of life after stroke: a prospective study.

Guajardo VD, Terroni L, Sobreiro Mde F, Zerbini MI, Tinone G, Scaff M, Iosifescu DV, de Lucia MC, Fráguas R.

J Stroke Cerebrovasc Dis. 2015 Jan;24(1):201-9. doi: 10.1016/j.jstrokecerebrovasdis.2014.08.020. Epub 2014 Nov 12.

PMID:
25440338
12.

Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.

Murrough JW, Burdick KE, Levitch CF, Perez AM, Brallier JW, Chang LC, Foulkes A, Charney DS, Mathew SJ, Iosifescu DV.

Neuropsychopharmacology. 2015 Mar 13;40(5):1084-90. doi: 10.1038/npp.2014.298.

PMID:
25374095
13.

Ketamine safety and tolerability in clinical trials for treatment-resistant depression.

Wan LB, Levitch CF, Perez AM, Brallier JW, Iosifescu DV, Chang LC, Foulkes A, Mathew SJ, Charney DS, Murrough JW.

J Clin Psychiatry. 2015 Mar;76(3):247-52. doi: 10.4088/JCP.13m08852.

PMID:
25271445
14.

The effect of personalized guideline-concordant treatment on quality of life and functional impairment in bipolar disorder.

Sylvia LG, Rabideau DJ, Nierenberg AA, Bowden CL, Friedman ES, Iosifescu DV, Thase ME, Ketter T, Greiter EA, Calabrese JR, Leon AC, Ostacher MJ, Reilly-Harrington N.

J Affect Disord. 2014 Dec;169:144-8. doi: 10.1016/j.jad.2014.08.019. Epub 2014 Aug 20.

PMID:
25194782
15.

Illness progression, recent stress, and morphometry of hippocampal subfields and medial prefrontal cortex in major depression.

Treadway MT, Waskom ML, Dillon DG, Holmes AJ, Park MT, Chakravarty MM, Dutra SJ, Polli FE, Iosifescu DV, Fava M, Gabrieli JD, Pizzagalli DA.

Biol Psychiatry. 2015 Feb 1;77(3):285-94. doi: 10.1016/j.biopsych.2014.06.018. Epub 2014 Jul 3.

PMID:
25109665
16.

Dissociable cortico-striatal connectivity abnormalities in major depression in response to monetary gains and penalties.

Admon R, Nickerson LD, Dillon DG, Holmes AJ, Bogdan R, Kumar P, Dougherty DD, Iosifescu DV, Mischoulon D, Fava M, Pizzagalli DA.

Psychol Med. 2015 Jan;45(1):121-31. doi: 10.1017/S0033291714001123. Epub 2014 May 15.

PMID:
25055809
17.

Executive function and depressive symptoms of retardation in nonelderly stroke patients.

Sobreiro MF, Miotto EC, Terroni L, Tinone G, Iosifescu DV, de Lucia MC, Scaff M, Leite Cda C, Amaro E Jr, Fraguas R.

J Clin Exp Neuropsychol. 2014;36(6):636-47. doi: 10.1080/13803395.2014.925092.

PMID:
24974834
18.

Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: examining the convergence of performance-based measures and self-reports.

Kaye JL, Dunlop BW, Iosifescu DV, Mathew SJ, Kelley ME, Harvey PD.

J Psychiatr Res. 2014 Oct;57:51-7. doi: 10.1016/j.jpsychires.2014.06.002. Epub 2014 Jun 12.

PMID:
24974001
19.

Biomarkers in major depressive disorder: the role of mass spectrometry.

Woods AG, Iosifescu DV, Darie CC.

Adv Exp Med Biol. 2014;806:545-60. doi: 10.1007/978-3-319-06068-2_27. Review.

PMID:
24952202
20.

Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial.

Dunlop BW, Rothbaum BO, Binder EB, Duncan E, Harvey PD, Jovanovic T, Kelley ME, Kinkead B, Kutner M, Iosifescu DV, Mathew SJ, Neylan TC, Kilts CD, Nemeroff CB, Mayberg HS.

Trials. 2014 Jun 21;15:240. doi: 10.1186/1745-6215-15-240.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk